Verition Fund Management
ALXN

Verition Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Verition Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-380,182
Closed -$69.8M – 2524
2021
Q2 		$69.8M Buy
380,182
+228,374
+150% +$39.2M 0.64% 33
2021
Q1 		$23.2M Buy
151,808
+1,707
+1% +$264K 0.26% 48
2020
Q4 		$23.5M Buy
150,101
+140,456
+1,456% +$18M 0.21% 80
2020
Q3 		$1.1M Sell
9,645
-1,742
-15% -$188K 0.02% 358
2020
Q2 		$1.28M Buy
+11,387
New +$1.21M 0.04% 338
2020
Q1 		– Sell
-9,131
Closed -$988K – 1180
2019
Q4 		$988K Sell
9,131
-136
-1% -$14.5K 0.02% 453
2019
Q3 		$908K Sell
9,267
-11,967
-56% -$1.35M 0.03% 438
2019
Q2 		$2.78M Buy
21,234
+8,560
+68% +$1.1M 0.08% 178
2019
Q1 		$1.71M Sell
12,674
-5,843
-32% -$727K 0.07% 254
2018
Q4 		$1.8M Buy
18,517
+16,362
+759% +$1.93M 0.13% 146
2018
Q3 		$300K Sell
2,155
-945
-30% -$119K 0.01% 1032
2018
Q2 		$385K Buy
3,100
+919
+42% +$107K 0.02% 785
2018
Q1 		$243K Buy
+2,181
New +$261K 0.02% 920
2017
Q4 		– Sell
-3,835
Closed -$538K – 1343
2017
Q3 		$538K Buy
+3,835
New +$521K 0.04% 539
2017
Q2 		– Sell
-1,757
Closed -$213K – 1395
2017
Q1 		$213K Buy
+1,757
New +$227K 0.02% 1012
2016
Q4 		– Sell
-3,240
Closed -$397K – 1489
2016
Q3 		$397K Sell
3,240
-5,005
-61% -$644K 0.04% 613
2016
Q2 		$963K Buy
+8,245
New +$1.17M 0.12% 190
2015
Q2 		– Sell
-1,633
Closed -$283K – 750
2015
Q1 		$283K Buy
+1,633
New +$296K 0.03% 217
2014
Q3 		– Sell
-2,830
Closed -$442K – 916
2014
Q2 		$442K Buy
2,830
+1,288
+84% +$203K 0.05% 289
2014
Q1 		$235K Buy
+1,542
New +$245K 0.04% 344
2013
Q4 		– Sell
-3,229
Closed -$375K – 708
2013
Q3 		$375K Buy
3,229
+823
+34% +$90.3K 0.06% 263
2013
Q2 		$222K Buy
+2,406
New +$232K 0.04% 461

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Verition Fund Management's ALXN Position: Q3 2021 in Review

Verition Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 380,182 shares — an estimated $69.8M sold.

Verition Fund Management first reported a position in ALXN in Q2 2013 and held it in 22 quarters. The position peaked at $69.8M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Verition Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Verition Fund Management sold 380,182 Alexion Pharmaceuticals shares in Q3 2021, an estimated $69.8M.
  • Verition Fund Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Verition Fund Management's Alexion Pharmaceuticals position peaked at $69.8M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Verition Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.